Metastatic Breast Cancer: 25-Year Survival Story
- Here's a breakdown of the important facts from the provided text regarding brain metastases (BM) in breast cancer patients:
- * The overall survival from breast cancer diagnosis to death was approximately 2 years (21.6 months).
- * HER2+ & TNBC: Patients diagnosed after 2014 had significantly longer survival compared to those diagnosed earlier.
Key Takeaways from the Text:
Here’s a breakdown of the important facts from the provided text regarding brain metastases (BM) in breast cancer patients:
1. Overall Survival (rwOS):
* The overall survival from breast cancer diagnosis to death was approximately 2 years (21.6 months).
* Survival varied significantly based on breast cancer subtype:
* HER2+: Best survival (31.0 months)
* HR+/HER2-: Intermediate survival (19.6 months)
* TNBC: Worst survival (12.8 months)
2. Temporal Trends (Improvements Over Time):
* HER2+ & TNBC: Patients diagnosed after 2014 had significantly longer survival compared to those diagnosed earlier.
* HER2+: 41.2 months vs.26.2 months (P =.002)
* TNBC: 14.9 months vs.7.0 months (P = .020)
* HR+/HER2-: No meaningful improvement in survival was seen over time (16.5 vs 21.6 months, P = .089). This is identified as an area of unmet need.
3. Prognostic Factors (What Impacts Survival):
* Positive Factors (Longer Survival):
* HER2 positivity
* Surgical resection of BM
* diagnosis after 2014
* Negative Factors (Shorter Survival):
* TNBC
* 6-10 BMs at diagnosis
* extracranial metastatic disease
* Leptomeningeal disease
4. Cohort Characteristics:
* Median age at BM diagnosis: 53 years
* Median time from breast cancer diagnosis to BM diagnosis: 8.1 months (shortest for TNBC – 2.8 months, longest for HR+/HER2- – 16.2 months)
* Most patients (75%+) had extracranial disease at BM diagnosis.
* Most patients received radiation (95.2%) and a substantial portion underwent surgery (30%).
5. Treatments Used:
* Many patients received CNS-penetrant therapies:
* HER2-targeted tkis (19.6%)
* Abemaciclib (2.8%)
* T-DM1 (8.7%)
* T-DXd (10.3%)
* Sacituzumab govitecan (5.9%)
* checkpoint inhibitors (6.9%)
In essence, the study highlights that while survival for some breast cancer subtypes with brain metastases is improving (especially HER2+ and TNBC), patients with HR+/HER2- disease are not experiencing the same benefits and require new treatment options.